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fact, assess ischemic episodes throughout the recording period and found
that there was not a significant difference in the rate of positive ECG
recordings for ischemia (19.9% on ranolazine vs. 21.0% on placebo; p
0.21) (3). The investigators did not specifically report the individual
number of symptomatic and silent episodes of myocardial ischemia or
their duration duringECGmonitoring on ranolazine versus placebo.The
aggregate risk of cardiovascular death or myocardial infarction in the
MERLIN–TIMI 36 trial was similar for patients taking ranolazine and
placebo and in the patient subset that was enrolled with prior chronic
angina, fewer recurrent ischemic episodes were observed in the
ranolazine-treated group after 1-year follow-up, and exercise durationwas
significantly greater (4). Thus, the hypothesis that converting symptom-
atic to silent ischemic episodes with ranolazine is harmful is unlikely to be
valid.
It would be interesting for the TIMI investigators to address the
specific question of the proportion of the number and duration of
asymptomatic and symptomatic ischemia episodes in patients taking
ranolazine versus placebo from their extensive continuous ECG
database and to correlate these findings with 1-year outcome. This
type of analysis would expand our knowledge on ranolazine treatment
effects and could potentially more completely address the question
that Dr. Conti has raised.
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Clopidogrel After Coronary
Artery Bypass Graft Surgery
Insufficient Evidence
We recently read the interesting study by Sørensen et al. (1), which
valuated the efficacy of clopidogrel after coronary artery bypass graft
urgery (CABG) following a recent myocardial infarction (MI). Usingdata from 3,545 patients, the authors reported a lower risk of death
and the combined endpoint of death or recurrent MI in patients who
received clopidogrel after surgery. Based on their results, the authors
recommend that a “focus on discharge clopidogrel treatment of these
patients should be made” (1).
Because their study was nonrandomized, the authors used multi-
variate and propensity-score analyses to control for possible confound-
ers. Interestingly though, no adjustment was made for the use of on-
or off-pump CABG. In theory, any benefit associated with clopi-
dogrel after CABGwould be seen in an improvement in graft patency
and the prevention of myocardial events. However, clopidogrel did
not significantly reduce the incidence of recurrent MI, cardiovascular
death, or the need for repeat revascularization in this study. How
could clopidogrel lower the risk of death and yet not reduce the
incidence of myocardial events after CABG? Although no explana-
tion was provided by the authors, perhaps this finding relates to
residual confounding. Clopidogrel may have been administered pref-
erentially to healthier patients in this cohort who were believed to have
a better chance for long-term survival.
Sørensen et al. (1) imply in their paper that clopidogrel is
underused after CABG, referring to the current guidelines that
recommend postoperative clopidogrel treatment for 9 to 12 months
for patients who undergo CABG following MI (2). This recommen-
dation was based primarily on data from the Clopidogrel in Unstable
Angina to Prevent Recurrent Ischemic Events (CURE) trial that
reported significantly fewer adverse cardiac events amongMI patients
treated with the combination of clopidogrel and aspirin compared
with aspirin alone, even if they ultimately underwent CABG (3).
However, subgroup analysis later revealed that the benefit of com-
bined antiplatelet therapy was entirely preoperative while patients
were awaiting surgery. No benefit was seen for clopidogrel use after
CABG in the CURE trial (4). Therefore, it is not surprising that
many surgeons do not routinely prescribe clopidogrel after CABG.
Because of the lack of prospective data in the field (5), we recently
performed the CASCADE (Clopidogrel After Surgery for Coronary
Artery DiseasE) study (NCT00228423), a randomized, placebo-
controlled trial to evaluate whether the addition of clopidogrel to aspirin
would inhibit the process of saphenous vein graft disease afterCABG (6).
Compared with aspirin alone, the combination of aspirin plus clopidogrel
did not significantly reduce vein graft intimal hyperplasia 1 year after
CABG, as assessed by intravascular ultrasound. Although CASCADE
was not powered for angiographic or clinical outcomes, we also did not
see a significant difference in vein graft patency or cardiovascular events
between the 2 treatment groups (7). Power calculations based on
CASCADE determined that a sample size of 8,000 grafts would be
required to demonstrate an improvement in patency with clopidogrel.
We doubt a future trial of this size will ever be performed.
In summary, based on the data available to date, we do not believe
that compelling evidence exists to support the routine use of clopi-
dogrel after CABG.
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The Unknown Effect of
Clopidogrel Resistance in Dual
Antiplatelet Therapies After
Coronary Artery Bypass Grafting
We read with great interest the article of Sørensen et al. (1) that
reported the efficacy of post-operative clopidogrel treatment in a
large patient cohort revascularized with coronary artery bypass
graft surgery (CABG) after myocardial infarction. Notwithstand-
ing the criterion of preoperative myocardial infarction, it remains
interesting that this result is contrary to the CASCADE (Clopi-
dogrel After Surgery for Coronary Artery DiseasE) trial, where
addition of clopidogrel to aspirin revealed no changes on the
post-operative outcomes (survival, 1-year intimal hyperplasia) (2).
A possible explanation could be the different rates of aspirin and/or
clopidogrel resistance between the 2 populations.
Aspirin resistance after cardiac surgery varies between 7% and
54% (depending on the platelet assay) (3). In contrast, clopidogrel
response in patients undergoing CABG remains unknown due to
the fact that aspirin is the drug of first choice after CABG, and
clopidogrel administration (in addition to aspirin) is recommended
mainly in patients with acute coronary syndrome (1). However,
previous reports indicate that the clopidogrel resistance rate in
coronary stent patients varies between 5% and 56% (4). Besides,
carriers of defective alleles for CYP2C19 and CYP2C9 and patients
undergoing omeprazole and atorvastatin therapy (inhibitors ofCYP2C19 and CYP3A4, respectively) are at risk of clopidogrel
resistance as well (5).
Certainly, the considerably high prevalence of clopidogrel resis-
tance in noncardiac surgery patients creates the necessity for
assessment of clopidogrel nonresponders undergoing CABG.
Otherwise, it remains unknown in dual antiplatelet therapies
whether the response to clopidogrel covers a possible aspirin
resistance or vice versa. Finally, we congratulate the authors for this
excellent and well-defined study and for their contribution to the
optimization of the clinical outcomes in patients undergoing
CABG after myocardial revascularization.
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Reply
We read with interest the letters by Drs. Kulik and Ruel and by
Dr. Bisdas and colleagues commenting on our study about the
efficacy of clopidogrel treatment in patients with myocardial
infarction (MI) treated with coronary artery bypass graft surgery
(CABG) (1).
Our study was a nationwide cohort study based on exact
information from nationwide registers of claimed prescriptions and
hospitalizations in Denmark. Although these registers include
comprehensive data, some details are not listed, for example,
on-pump/off-pump, whereas platelet function tests are currently
not recommended for routine use (2). Including these variables
might have increased the accuracy of our models, but we do not
believe it would have changed the results substantially. Impor-
tantly, we found reduced mortality among patients receiving
clopidogrel after CABG. This finding was consistent in the
propensity-matched subgroup analysis. We did not find reduced
recurrent MIs. However, contrary to the statement by Drs. Kulik
and Ruel, we found reduced cardiovascular death among the
